When pharmaceutical developers evaluate an analytical development company in India, their focus centres on method stability, regulatory defensibility, and audit-ready data packages. Whether identifying low-level genotoxic impurities or resolving co-eluting degradants under accelerated stress, sponsors require analytical methods that perform without fail across multiple laboratories.
At KMS Pharma, our analytical scientists operate with phase-appropriate precision and strict 21 CFR Part 11 adherence. Supporting innovator candidates, 505(b)(2) programs, and complex generic filings targeting the USFDA, EMA, MHRA, and CDSCO, we design methods that stand up to regulatory review and commercial QC batch release.
Why global sponsors partner with Indian analytical testing laboratories
Analytical development has progressed far beyond routine release testing. Today, it forms the scientific backbone of regulatory filings, Quality by Design (QbD) control strategies, and lifecycle management. Sponsors across North America, Europe, and Asia-Pacific regularly turn to analytical development laboratories in India to execute comprehensive testing regimens with high speed and scientific depth.
Partnering with an analytical development laboratory in India gives pharmaceutical teams access to advanced chromatography and mass spectrometry platforms, run by scientists experienced in pharmacopeial frameworks (USP, Ph. Eur., BP, IP). Projects benefit from faster turnaround times on forced degradation and screening protocols, helping development teams identify failure modes before formal stability registration begins.
Broad analytical instrumentation: Access to UHPLC, HPLC, LC-MS/MS, GC-MS/MS, ICP-MS, and automated dissolution systems without heavy internal capital expenditure.
Experienced analytical chemists: Teams skilled at troubleshooting complex separations, tailing peaks, matrix interference, and poorly soluble compounds.
Regulatory audit trail compliance: End-to-end ALCOA+ data management with secure electronic audit trails, automated back-ups, and strict access controls.
Cost-effective method execution: Comprehensive method optimization and forced degradation studies executed at manageable operational costs.
Phase-appropriate method development and optimization
A robust analytical assay requires balanced mobile phases, appropriate column chemistry, and clear baseline separation. An unstable method creates significant operational risk, leading to out-of-specification (OOS) investigations, false positives, and costly regulatory delays during commercial manufacturing.
KMS Pharma develops phase-appropriate analytical methods tailored to the molecule's stage of development. From early exploratory assays used in formulation screening to stability-indicating commercial methods, our team systematically evaluates stationary phases, gradient profiles, pH windows, and column temperatures to achieve baseline resolution between active ingredients, degradants, excipients, and counter-ions.
Physicochemical Profiling
Assessing pKa, LogP/LogD, UV-Vis spectra, solubility profiles, and degradation pathways to define ideal chromatographic modes (reverse phase, normal phase, HILIC, or ion exchange).
Column & Mobile Phase Screening
Systematic screening of C18, C8, phenyl-hexyl, and cyano phases alongside diverse buffer compositions to balance retention times and peak symmetry.
Gradient & Flow Optimization
Refining gradient slopes, flow rates, injection volumes, and detector wavelengths to ensure sharp separation with minimal solvent waste.
Method Stress Testing
Evaluating method resilience against intentional variations in pH (±0.2 units), column temperature (±5°C), and organic ratios (±2%) before formal validation.
ICH Q2(R2) analytical method validation
Once a method is optimized, it must undergo formal validation to demonstrate suitability for its intended analytical purpose. Regulatory health authorities expect method validation dossiers to be structured in accordance with ICH Q2(R2) and pharmacopeial standards (USP ⟨1225⟩ / USP ⟨621⟩).
KMS Pharma executes comprehensive method validation protocols covering assays, related substances, residual solvents, and dissolution testing. Our validation documentation includes raw chromatograms, statistical evaluations, and clearly defined system suitability criteria to ensure straightforward review by regulatory auditors.
Specificity & Forced Degradation
Subjecting active ingredients and finished products to acid, base, peroxide, thermal, and photolytic stress to demonstrate peak purity and lack of co-elution using diode array detectors (DAD) and mass spectrometry.
Linearity, Range & Sensitivity
Establishing regression coefficients (r² ≥ 0.999) across targeted working ranges, and determining precise Limits of Detection (LOD) and Limits of Quantitation (LOQ) using signal-to-noise and standard deviation approaches.
Precision & Intermediate Precision
Confirming repeatability through six replicate preparations and verifying intermediate precision across multiple days, different instruments, and separate analysts to ensure reproducible results.
Accuracy & Recovery Across Levels
Evaluating recovery rates by spiking known impurity and API concentrations into product placebos at 50%, 100%, and 150% of the target specification, confirming absence of matrix interference.
Impurity profiling, nitrosamines, and extractables & leachables
Regulatory expectations for impurity control are more stringent than ever. Drug developers must detect, quantify, and control degradation products, elemental impurities, residual process solvents, and cohort-of-concern genotoxins at parts-per-billion (ppb) levels.
KMS Pharma provides high-sensitivity mass spectrometry workflows to tackle complex impurity profiles. Our testing programs align with ICH Q3A/B (organic impurities), ICH Q3C (residual solvents), ICH Q3D (elemental impurities), and ICH M7 guidelines for mutagenic and carcinogenic risks.
Targeted LC-MS/MS and GC-MS/MS methods for NDMA, NDEA, NDIPA, and NDSRIs down to trace picogram thresholds.
Class 1, 2A, 2B, and 3 element quantitation via closed-vessel microwave digestion and ICP-MS analysis.
Headspace GC-FID/MS methods for volatile organic compounds, Class 1 toxic solvents, and reaction carriers.
Controlled extraction studies on primary container closures, elastomer stoppers, foil blister packs, and delivery devices.
High-resolution mass spectrometry (HRMS) and preparative isolation to characterize degradation products exceeding identification thresholds.
SEC, ion-exchange, and peptide mapping to monitor purity, post-translational modifications, and high-molecular-weight species.
Discriminatory and biorelevant dissolution testing
Dissolution testing serves as the critical bridge connecting formulation development, in-vivo pharmacokinetic performance, and commercial batch quality control. Developing a discriminatory dissolution method is essential for detecting critical material changes, coating differences, and manufacturing variances before products reach patients.
Our dissolution laboratories support USP Apparatus 1 (Basket), Apparatus 2 (Paddle), and specialized dissolution systems. We develop biorelevant dissolution media—including Fasted State Simulated Intestinal Fluid (FaSSIF), Fed State Simulated Intestinal Fluid (FeSSIF), and simulated gastric fluids—to establish meaningful in-vitro in-vivo correlations (IVIVC) that help de-risk bioequivalence studies.
Discriminatory power verification: Demonstrating method sensitivity against variations in API particle size, lubrication time, and tablet compression force.
Multi-media dissolution profiling: Dissolution evaluation across pH 1.2, 4.5, and 6.8 buffer media to build robust f1 (difference) and f2 (similarity) comparisons.
Automated autosampling systems: Precision-timed sampling interfaces that eliminate manual extraction errors and sample carryover.
Surfactant screening & sink conditions: Scientific selection of SLS, Tween, or CTAB to achieve sink conditions for poorly water-soluble BCS Class II/IV molecules.
ICH stability testing and environmental storage chambers
Generating dependable stability data is a fundamental prerequisite for establishing shelf life and securing marketing authorizations. Stability programs must be conducted in validated environmental chambers subject to continuous temperature and humidity telemetry monitoring.
KMS Pharma maintains stability storage facilities covering all major ICH climatic zones. Our stability testing programs operate under validated laboratory information management systems (LIMS), providing transparent time-point tracking, automated testing alerts, and defensible shelf-life projections.
Reliable analytical data isn't just about meeting regulatory requirements—it protects product quality and commercial timelines across the lifecycle.
Temperate & Subtropical
Long-term storage at 25°C / 60% RH and intermediate conditions at 30°C / 65% RH for North American, European, and Japanese market filings.
Hot & Humid Markets
Dedicated chambers operating at 30°C / 75% RH and accelerated conditions at 40°C / 75% RH for ASEAN, Middle Eastern, and Latin American dossiers.
Refrigerated & Frozen
Monitored cold storage at 2°C to 8°C and deep-freeze chambers (-20°C and -80°C) for temperature-sensitive parenterals, peptides, and biologics.
ICH Q1B Photostability
Exposure testing exceeding 1.2 million lux hours and 200 watt-hours/m² near-UV energy to assess primary packaging light-barrier performance.
Analytical method transfer and commercial site handover
An analytical method that operates successfully in an R&D development lab must transfer cleanly into commercial quality control (QC) facilities. Variations in laboratory ambient conditions, instrument models, plumbing configurations, and analyst techniques can cause unexpected method transfer failures.
At KMS Pharma, method transfer is treated as a structured, risk-managed workflow governed by formal protocols and pre-defined acceptance criteria. We work closely with receiving QC laboratories to ensure smooth method adoption without unexpected chromatographic variation.
Formal transfer protocols: Detailed documents establishing comparative testing parameters, acceptable intermediate precision limits, and predefined passing thresholds.
Direct analyst training & demonstration: Side-by-side execution and live technical handover between donor scientists and receiving lab QC analysts.
Comparative testing execution: Independent analysis of homogeneous reference and batch samples by both laboratories to confirm statistical equivalence.
Comprehensive transfer reports: Complete data packages, system suitability documentation, and sign-offs for CTD Module 3.2.P.5.3 regulatory inclusion.
Checklist: Selecting an analytical development partner in India
Outsourcing analytical development requires careful evaluation of technical capability, regulatory familiarity, and operational transparency. Before finalizing an analytical services agreement, confirm that your testing partner meets these fundamental operational standards:
Strict electronic data integrity: Verified audit trails, restricted administrative controls, and validated chromatography data systems (e.g., Empower, Chromeleon) complying with 21 CFR Part 11.
Experience with your specific dosage form: Demonstrated track record resolving testing challenges for oral solids, sterile parenterals, topicals, or inhalations.
Dedicated forced degradation workflows: Clear protocols for distinguishing true process impurities from degradants generated under stress conditions.
Direct access to principal scientists: Open technical review calls, fast-turnaround deviation reporting, and collaborative method troubleshooting.
Complete intellectual property protection: Clear contractual agreements ensuring all analytical methods, validation reports, and raw data remain your exclusive property.
Partner with KMS Pharma for reliable analytical development
Looking to develop stability-indicating assays, resolve complex impurity profiles, or validate methods for regulatory submission? Speak directly with our senior analytical development team in India to discuss your project requirements.
Request Analytical Consultation